Views & Analysis | Perspectives on pharma industry issues

Sales & Marketing

Woman shakes man's hand in hiring process

Changing Faces: Agency and consultancy, January 2026

The pharmaceutical services sector saw a flurry of new executive hires last month, spanning agencies, consultancies, investment firms & a few others.

R&D

Sponsored

Best practices in cardiometabolic trial design: Planning and...

Cardiometabolic disease is not a single entity. It is a broad spectrum of disorders that share common drivers.

R&D

Whole-genome sequencing in the UK and Europe, with Mark Robi...

Whole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation.

Patients

Precision medicine in action, with Cary Claiborne

Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.

Patients

pharmaphorum podcast Episode 244, Jeff Harper - IntelliGuard

On addressing drug waste and ensuring access, with Jeff Harp...

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

Sales & Marketing

Sponsored

Company Profile – POA Pharma

In a landscape shaped by regulatory complexity, POA Pharma is demonstrating that smart, regionally tailored growth can outperform scale.

Oncology

Why functional cancer profiling has the potential to transfo...

Functional cancer profiling is an important step forward in the progress of oncology treatment, with the potential to transform patient outcomes.

Sales & Marketing

Changing Faces: Agency and consultancy, January 2026

The pharmaceutical services sector saw a flurry of new executive hires last month, spanning agencies, consultancies, investment firms & a few others.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Digital

Activation of the G protein-coupled GABA B receptor by the agonist baclofen

How GenAI is cracking the toughest targets in drug discovery

Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Patients

Precision medicine in action, with Cary Claiborne

Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.

Patients

On addressing drug waste and ensuring access, with Jeff Harp...

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.

Patients

Sponsored

From insight to impact: Why the patient voice will redefine ...

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

R&D

Sponsored

Changing Faces: Agency and consultancy, January 2026

Best practices in cardiometabolic trial design: Planning and...

Whole-genome sequencing in the UK and Europe, with Mark Robi...

Precision medicine in action, with Cary Claiborne

On addressing drug waste and ensuring access, with Jeff Harp...

Biotech’s biggest challenge isn’t scientific, but political ...

Company Profile – POA Pharma

Why functional cancer profiling has the potential to transfo...

Changing Faces: Agency and consultancy, January 2026

Four reasons pharma is sweeping the Super Bowl despite FDA f...

From engagement metrics to meaningful experience: Why pharma...

How GenAI is cracking the toughest targets in drug discovery

Biotech leaders: ‘They're shoving this industry into the arm...

European biopharma at a crossroads

A cancer treatment modality that prioritises QoL, with Ben Z...

Improving breast cancer outcomes in sub-Saharan Africa

Engineering “smarter” cells, with Tim Lu

Precision medicine in action, with Cary Claiborne

On addressing drug waste and ensuring access, with Jeff Harp...

From insight to impact: Why the patient voice will redefine ...

Best practices in cardiometabolic trial design: Planning and...

Whole-genome sequencing in the UK and Europe, with Mark Robi...

AMR and vaccines: Can universal coverage avert a post-antibi...

BridgeBio gains on phase 3 dwarfism data

How to meet your physicians where they are online

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks